Hydropathic anticomplementarity of amino acids indicates that peptides derived from complementary DNA strands may form amphiphilic structures and bind one another. By using this concept, we have found that the antisense peptide Ser-Tyr-Asp-Leu complementary to the segment GlnIle-Val-Ala-Gly (residues 55-59) in cystatin C (an inhibitor of cysteine proteases) is located at positions 611-614 of the 18 chain of human C4, the fourth component of complement. Here we describe and characterize the specific interaction between cystatin C and C4 by ligand affinity chromatography and ELISA. Interaction between the two native proteins was mimicked on replacement of one of them with the corresponding sense-antisense peptide coupled to a carrier protein, and the binding was inhibited by these synthetic peptides in solution. Through the interaction with C4, cystatin C may play a regulatory role in complement activation that might be of particular importance at tissue sites where both proteins are produced by macrophages.
ABSTRACT
Hydropathic anticomplementarity of amino acids indicates that peptides derived from complementary DNA strands may form amphiphilic structures and bind one another. By using this concept, we have found that the antisense peptide Ser-Tyr-Asp-Leu complementary to the segment GlnIle-Val-Ala-Gly (residues 55-59) in cystatin C (an inhibitor of cysteine proteases) is located at positions 611-614 of the 18 chain of human C4, the fourth component of complement. Here we describe and characterize the specific interaction between cystatin C and C4 by ligand affinity chromatography and ELISA. Interaction between the two native proteins was mimicked on replacement of one of them with the corresponding sense-antisense peptide coupled to a carrier protein, and the binding was inhibited by these synthetic peptides in solution. Through the interaction with C4, cystatin C may play a regulatory role in complement activation that might be of particular importance at tissue sites where both proteins are produced by macrophages.
Human cystatin C (formerly y trace) (1) is a basic protein of known primary structure (2) fully distributed in body fluids in a wide concentration range. It has been localized immunocytochemically in some cortical neurons, LH cells of the adenohypophysis, pancreatic A and thyroid C cells, and adrenal medulla (3) . It is secreted into tissue culture medium by monocytes and other cells, and the down-regulation of its secretion may play a role in inflammation (4) .
Structural and genetic studies indicate that cystatin C is part of a superfamily that comprises three families, types I, II, and III (5, 6) . Type I cystatins (also called stefins) are proteins of "100 residues with no disulfide bonds. Type II cystatins (family that includes cystatin C) are molecules of 115-120 amino acids with two disulfide loops near the C terminus. Type III cystatins (kininogens) are high molecular weight proteins (Mr 68,000-110,000) composed of three cystatin type II-like domains (about 360 residues), the bradykinin moiety (9 amino acids), and a C-terminal polypeptide of variable length.
Cystatins possess inhibitory activity against a broad spectrum of cysteine proteinases of plant origin (papain, chymopapain, ficin, and actinidin) as well as mammalian lysosomal proteases such as cathepsins B, H, and L (for review, see ref. 7) . The active site of inhibitory activity remains unknown, although some evidence suggests involvement of glycine at position 11 (8) and the segment 55-59 (cystatin C numbering) (6, 9, 10), both highly conserved in all known cystatins (7) . Moreover, peptide Leu-Val-Gly (positions 9-11) inhibits growth of many bacteria, especially all group A streptococci, apparently due to inhibition of a cysteine protease produced by the bacteria (11) .
In addition to the inhibitory activity, the above-mentioned residues (almost identical in all members of the cystatin superfamily) may also be involved in protein-protein interactions. It is known that there is a tendency in the genetic code for codons of hydrophilic amino acids to be complemented by codons of hydrophobic amino acids, resulting in peptide structures that might interact specifically through amphiphilic conformations (12) . It was shown that peptides generated from the noncoding strand of DNA specifically recognize segments coded by the complementary strand (13) . This concept was successfully used in the demonstration of the interaction between different peptide pairs (14) as well as in the purification of several receptors, among them corticotropin (ACTH) (13) , fibronectin (15) , and angiotensin II (16) . Practical application of this approach is restricted to systems in which DNA sequence information is available. We have taken advantage of our recent report on the nucleotide sequence of the gene coding for cystatin C (17); from the sequence coding for the segment Gln-Ile-Val-Ala-Gly (residues 55-59), we have deduced the complementary DNA strand and, hence, the amino acid sequence of the antisense peptide. We now present evidence of the specificity and saturability of the interaction between cystatin C and the complementary deduced peptide Ser-Tyr-Asp-Leu and demonstrate that a protein containing the antisense peptide (human C4, the fourth component of complement) interacts with cystatin C and that this binding is inhibited by the antisense peptide.
MATERIALS AND METHODS
Proteins, Synthetic Peptides, and Antibodies. Human cystatin C was isolated from urine as described (18) . C4 was purified from human plasma according to Gresham et al. (19) with modifications: 20 ml of whole plasma containing 10 mM EDTA, 10 mM benzamidine hydrochloride, 5% L-lysine (free base), and 1 mM phenylmethylsulfonyl fluoride was precipitated with PEG 6000 (final concentration, 5%) for 1 hr at 4°C. After centrifugation at 40,000 x g for 30 min, the pellet was discarded and the supernatant was made 21% in PEG 6000 to precipitate C3 and C4. The pellet was redisolved in 3 mM phosphate buffer (pH 7.3) containing 6.5 mM EDTA, 6.5 mM benzamidine hydrochloride, 33 mM E-amino caproic acid, and 61.5 mM NaCl and applied to a 60-ml DEAE-Sephacel (Pharmacia) column equilibrated with the same buffer. After washing off the unbound material, the column was sequentially eluted with 200 ml of a linear NaCI gradient (100 ml of 3 mM phosphate/65 mM NaCI, pH 7.3, and 100 ml of 3 mM phosphate/133 mM NaCI, pH 7.3), washed with 100 ml of 3 mM phosphate/133 mM NaCl, pH 7.3, and eluted again with 200 ml of a linear NaCl gradient (100 ml of 3 mM phosphate/ 133 mM NaCl, pH 7.3, and 100 ml of 3 mM phosphate/300 mM NaCl, pH 7.3). As a final purification step, C4 was Abbreviation: BSA, bovine serum albumin.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. precipitated with PEG 6000 (final concentration, 16%), redisolved in phosphate-buffered saline [(PBS) 20 mM phosphate/150 mM NaCl, pH 7.0], and stored at -70TC. Identification of C4 in the column fractions was achieved by immunodiffusion (20) and purity was assessed by SDS/ PAGE (21) .
Synthetic peptides Gln-Ile-Val-Ala-Gly, Ser-Tyr-Asp-Leu, Gin-Ile-Val-Ala-Gly-Cys, Ser-Tyr-Asp-Leu-Cys, Thr-TyrLys-Phe-Phe-Glu-Gln-Met-Gln-Asn-Cys, Asn-Trp-CysLys-Arg-Gly-Arg-Lys-Gln, and Asp-Glu-Leu-Leu-Gln-LysGlu-Gln-Asn-Tyr-Ser-Asp were synthesized in the Center for the Analysis and Synthesis of Macromolecules (State University of New York, Stony Brook) by solid-phase techniques (22) and further purified by high-performance liquid chromatography. Their purity was ascertained by amino acid analysis using a Waters Pico Tag system and by Edman degradation analysis on a 477A Applied Biosystems sequencer.
Peptides Gln-Ile-Val-Ala-Gly-Cys, Ser-Tyr-Asp-Leu-Cys, and Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn-Cys were coupled to bovine serum albumin (BSA) by way of their C-terminal cysteine, by use of the heterobifunctional reagent m-maleimido-benzoyl-N-hydroxysuccinimide ester (23) .
Anti-human cystatin C was produced in rabbits (24); rabbit anti-human C4 was purchased from Dako (Santa Barbara, CA); alkaline phosphatase-labeled goat F(ab')2 anti-rabbit IgG was acquired from Tago.
Affinity Chromatography Assays. Cystatin C and BSA were coupled to CNBr-activated Sepharose 4B (Pharmacia) at 5 mg/ml of beads according to manufacturer's instructions. Two sets of experiments were performed using cystatin C-Sepharose and control beads of BSA-Sepharose (columns of 1.5 ml each). In the first set, different amounts of C4 (0.5-2.5 mg) were allowed to interact with the affinity matrices equilibrated in 10 mM phosphate (pH 7.4) containing either 25 or 150 mM NaCl. In the second set, 1.0 mg of C4 was subjected to cystatin C affinity chromatography under different salt concentrations (0-150 mM NaCI). In all cases the columns were washed with the equilibrating buffer until no further material absorbing at 280 nm was detected. Bound protein was eluted with 1 M NaCl in the starting buffer. In both experiments, the amount of C4 was calculated using an extinction coefficient, el% , at 280 nm of 8.2 (25) .
Enzyme-Linked Immunosorbent Assay (ELISA). Plastic microtiter plates (Immulon 2; Dynatech) were coated (100 ,ul per well, overnight at 4°C) with the different proteins in 0.1 M NaHCO3 buffer at pH 9.6. Coating was terminated by two washes of TBS (20 mM Tris/150 mM NaCl, pH 7. Inhibition Assays. Synthetic peptides Ser-Tyr-Asp-Leu and Gln-Ile-Val-Ala-Gly as well as unrelated peptides ThrTyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn-Cys, Asn-TrpCys-Lys-Arg-Gly-Arg-Lys-Gln, and Asp-Glu-Leu-LeuGln-Lys-Glu-Gln-Asn-Tyr-Ser-Asp were screened for inhibition of binding by C4 and cystatin C. Different amounts of the synthetic peptides (0.1-10 ,ug) dissolved in 50/ul of50 mM Tris (pH 7.4) were added to 50 ng of either cystatin C or C4 in 50 ,ul of the same buffer and incubated 1 hr at room temperature. Aliquots of each mixture were transferred into Ser-Tyr-Asp-Leu-BSA-, C4-, cystatin C-, Gln-Ile-Val-AlaGly-BSA-, unrelated peptide-BSA-, or BSA-coated wells and the bound cystatin C or C4 was measured as above (see figure legends for details).
RESULTS AND DISCUSSION
The nucleotide and amino acid sequences of the segment 55-59 in cystatin C (the most conserved in all cystatins), the nucleic acid sequence of complementary DNA strand, and the amino acid sequence deduced for its protein translation prod- The interaction between cystatin C and C4 was studied by means ofaffinity chromatography and ELISA. As a first step, cystatin C and C4 were purified as in Materials and Methods; C4 was recovered from the DEAE-Sephacel columns at 270 mM NaCl. After precipitation with PEG, only one band ofMr 210,000 was detected in SDS/10% polyacrylamide gels, whereas, under reducing conditions, the three characteristic bands of C4 (Mr 90,000, Mr 80,000, and Mr 30,000) were found. Purified cystatin C was immobilized onto Sepharose 4B (1.5 mg/ml of beads) and allowed to react with purified C4. Fig. 2 shows that the interaction follows a dose-response relationship and that the binding is enhanced by lowering the NaCl concentration. The amount of protein bound increased residue* 55 -59 ) VAL ALA GLY ...
GTA GCT GGG GTG AAC
CAT CGA CCC CAC TTG almost 5-fold when the NaCl molarity was lowered from 150 mM to 10 mM (Fig. 3) , indicating that ionic forces are important in this binding.
A series of ELISA experiments was carried out to establish the role of the peptides Gln-Ile-Val-Ala-Gly and SerTyr-Asp-Leu in the interaction between cystatin C and C4. As shown in Fig. 4 , a dose-response relationship was obtained when cystatin C was added to increasing amounts of C4 or Ser-Tyr-Asp-Leu-BSA bound to the microtiter plates. Thus, the antisense peptide Ser-Tyr-Asp-Leu contained in C4 was able to mimic the behavior of C4 in its interaction with cystatin C, whereas BSA or an unrelated peptide-BSA yielded no binding activity. Ser-Tyr-Asp-Leu was coupled to BSA to avoid nonspecific interactions often observed when small peptides are coated onto microtiter plates (27) .
The reaction C4-cystatin C was inhibited by peptide Ser-Tyr-Asp-Leu in solution. When cystatin C was preincubated with increasing concentrations of Ser-Tyr-Asp-Leu before the assay, cystatin C binding to C4 decreased, as shown in Fig. 5 , corroborating the importance of the sequence Ser-Tyr-Asp-Leu (positions 611-614 of the C4) for the binding activity. Unrelated peptides preincubated with cystatin C under identical conditions failed to inhibit the interaction. The peptide Gln-Ile-Val-Ala-Gly (the sense sequence contained in cystatin C) coupled to BSA interacted with C4 in a dose-response relationship almost identical to that of cystatin C-C4 (Fig. 6) . BSA or an unrelated peptide-BSA was used as a control for nonspecific interaction.
Our results indicate that there is specific binding between cystatin C and C4, which contain in their sequences peptides encoded by complementary DNA strands. These sense and antisense peptides are able to mimic or inhibit the interaction between both proteins, indicating that they play a preeminent role in the binding activity. It will be important to establish the effect of certain amino acid substitutions on the interaction, since the recognition signal could require a special arrangement of charges and/or specific three-dimensional structure. Interestingly, very similar sequences can be found among proteins that are members of different interactive pathways. In this light, the residues Ser-His-Asp-Leu are present in prekallikrein and kallikrein, whereas kininogens of high and low molecular weight, also members of the cystatin superfamily, contain the sequence Gln-Val-Val-Ala-Gly, closely related to the sense peptide in cystatin C.
Although further studies are necessary to establish the biological relevance of these findings, we have evidence that the cystatin C-C4 interaction does indeed occur under physiological conditions. Preliminary studies indicate that cystatin C significantly inhibits the lytic activity of the classical complement pathway, preventing the erythrocyte/antibody/ complement 1-4 complex to bind C2 and form the C3 convertase (unpublished observations). It is widely known that complement activation is normally a local event occurring on cell membranes and antigen-antibody complexes. The biologically active peptides produced during the activation sequence are able to increase vascular permeability, attract and immobilize leukocytes at sites of inflammation, stimulate phagocytosis, and promote the formation of a cytolytic complex. This very powerful system is regulated by several plasma proteins (28) . The interaction described here could constitute a different regulatory mechanism for complement activation that may be of particular interest at tissue sites where cystatin C and the complement proteins are locally produced by macrophages (29, 30) .
